Drug intelligence / Profile preview

ET206

Development stage: Unknown
Lead developer: Expression Therapeutics

Overview

ET206 is a biological product initially developed by Expression Therapeutics. It is under investigation primarily for the treatment of neoplasms, with neuroblastoma specifically listed as an inactive indication. The drug's highest reported development phase is "Pending," with early Phase 1 activity noted in the United States. Detailed information about its mechanism of action, molecular target(s), or specific modality has not been disclosed in public sources as of June 2025[1][3].

Beyond the preview

Go deeper on ET206.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ET206.

Explore the full profile